Search Results 911-920 of 16392 for monoclonal antibody

1. Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma - Mayo Clinic

   Participation eligibility · Prior mogamulizumab. · Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of ...

2. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   ... monoclonal antibodies. Patients must not have received prior treatment with a VEGFR tyrosine kinase inhibitor. Except for Cohort D (MSS mCRC), patients must ...

3. Publications - Thanai Pongdee, M.D. - Mayo Clinic

   Hagan JB, Ender E, Divekar RD, Pongdee T, Rank MA. Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies. Mayo Clin Proc Innov Qual ...

4. Primary immunodeficiency - Symptoms & causes - Mayo Clinic

   B cell (antibody) deficiencies; T cell deficiencies; Combination B and T cell deficiencies; Defective phagocytes; Complement deficiencies; Unknown (idiopathic) ...

5. A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

   Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E (IgE) therapy ...

6. A2B101-101: Obtaining Solid Tumor Tissue from Subjects Having Surgical Resection for Certain Tumor Types and Leukapheresis for CAR T-cell Therapy Manufacturing - Mayo Clinic

   any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks ...

7. Multiple sclerosis - Symptoms and causes - Mayo Clinic

   Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024 ...

8. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC - Mayo Clinic

   (including monoclonal antibodies). 3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or ...

9. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

   Kaplan GG. Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Related.

10. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

    History of ≥ Grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of ...